Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

944 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Maffini E, Labopin M, Kröger N, Finke J, Stelljes M, Schroeder T, Einsele H, Tischer J, Bornhäuser M, Bethge W, Brecht A, Rösler W, Dreger P, Schäfer-Eckart K, Passweg J, Blau IW, Nagler A, Ciceri F, Mohty M. Maffini E, et al. Among authors: kroger n. Bone Marrow Transplant. 2024 Mar 30. doi: 10.1038/s41409-024-02275-6. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38555412
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.
Kröger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, Zabelina T, Fehse B, Ayuk F, Wittkowsky G, Schmitz N, Zander AR. Kröger N, et al. Blood. 2002 Dec 1;100(12):3919-24. doi: 10.1182/blood-2002-04-1150. Epub 2002 Aug 8. Blood. 2002. PMID: 12393448 Free article. Clinical Trial.
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Kröger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schäfer-Eckart K, Wittkowsky G, Schmitz N, Krüger W, Zabelina T, Renges H, Ayuk F, Krüll A, Zander A; German Study-group Multiple Myeloma (DSMM). Kröger N, et al. Bone Marrow Transplant. 2003 Jun;31(11):973-9. doi: 10.1038/sj.bmt.1704049. Bone Marrow Transplant. 2003. PMID: 12774047 Clinical Trial.
Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.
Kröger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A, Perez-Simon JA, San Miguel JF, Kiehl M, Fauser A, Schwerdtfeger R, Wandt H, Sayer HG, Myint H, Klingemann H, Zabelina T, Dierlamm J, Hinke A, Zander AR. Kröger N, et al. Blood. 2004 Jun 1;103(11):4056-61. doi: 10.1182/blood-2003-12-4435. Epub 2004 Feb 24. Blood. 2004. PMID: 14982868 Free article.
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauser A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF, Brand R, Zander AR. Kröger N, et al. Biol Blood Marrow Transplant. 2004 Oct;10(10):698-708. doi: 10.1016/j.bbmt.2004.06.002. Biol Blood Marrow Transplant. 2004. PMID: 15389436 Free article. Clinical Trial.
After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B.
Schetelig J, Breitschaft A, Kröger N, Zabelina T, Ebell W, Bornhäuser M, Haack A, Ehninger G, Salama A, Siegert W; Cooperative Transplantations Study Group. Schetelig J, et al. Among authors: kroger n. Transfusion. 2005 May;45(5):779-87. doi: 10.1111/j.1537-2995.2005.04236.x. Transfusion. 2005. PMID: 15847669
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.
Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhäuser M, Ayuk F, Zander AR, Marks DI; Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group. Kröger N, et al. Br J Haematol. 2005 Jun;129(5):631-43. doi: 10.1111/j.1365-2141.2005.05513.x. Br J Haematol. 2005. PMID: 15916686 Free article.
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Bornhäuser M, Kröger N, Schwerdtfeger R, Schafer-Eckart K, Sayer HG, Scheid C, Stelljes M, Kienast J, Mundhenk P, Fruehauf S, Kiehl MG, Wandt H, Theuser C, Ehninger G, Zander AR; Cooperative German Transplant Study Group. Bornhäuser M, et al. Among authors: kroger n. Eur J Haematol. 2006 Jan;76(1):9-17. doi: 10.1111/j.0902-4441.2005.t01-1-EJH2321.x. Eur J Haematol. 2006. PMID: 16343266
944 results